Status:

RECRUITING

Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy

Lead Sponsor:

Imperial College London

Collaborating Sponsors:

British Heart Foundation

Royal Brompton & Harefield NHS Foundation Trust

Conditions:

Dilated Cardiomyopathy

Cardiovascular Diseases

Eligibility:

All Genders

Up to 99 years

Brief Summary

Finding new ways to diagnose and treat Dilated Cardiomyopathy (DCM) could improve the health and well-being of patients with this condition. The main aim of this research study is to help develop bett...

Detailed Description

This study will recruit patients from a number of hospitals in England and study them over a number of years. The study will be divided in 2 parts. Part 1 will recruit patients with a diagnosis of DCM...

Eligibility Criteria

Inclusion

  • PART 1
  • Male or female participants of any age
  • Capacity to provide informed consent
  • Patients with a confirmed diagnosis of DCM
  • Affected family members of patients meeting diagnostic criteria for DCM

Exclusion

  • DCM attributed to chemotoxicity (from chemotherapeutic agents, drugs of abuse)
  • DCM attributed to systemic inflammatory myopathies (eg sarcoid, systemic lupus erythematosus)
  • Patients who lack capacity to consent for themselves
  • Patients with a confirmed history of coronary artery disease, assessed using standard UK clinical practice guidelines, defined as one or more of the following:-
  • \>50% narrowing, any major epicardial coronary artery on invasive or computed tomography coronary angiography
  • CMR suggestive of previous myocardial infarction of ≥2 segments of ≥50% infarction of the LV wall
  • Previous percutaneous coronary intervention or coronary bypass surgery
  • History of primary valvular heart disease or congenital heart disease
  • Severe, untreated or untreatable hypertension (systolic blood pressures routinely \>180 mm Hg and/or diastolic blood pressures \>120 mm Hg)
  • PART 2
  • Inclusion Criteria:
  • Males or females of any age
  • Capacity to provide informed consent
  • Patients with hypokinetic non-dilated cardiomyopathy, or
  • Family members of DCM patients with possible or probable DCM or
  • Patients with a confirmed diagnosis of heritable cardiovascular disease or
  • Family members of patients with heritable cardiovascular disease, both affected and unaffected

Key Trial Info

Start Date :

January 9 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 22 2027

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT03843255

Start Date

January 9 2020

End Date

July 22 2027

Last Update

March 31 2022

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom, LS1 3EX

2

Glenfield Hospital

Leicester, United Kingdom, LE3 9QP

3

Liverpool Heart and Chest Hospital NHS Foundation Trust

Liverpool, United Kingdom, L14 3PE

4

Royal Brompton & Harefield NHS Foundation Trust

London, United Kingdom, SW3 6NP